Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocular TherapeutixOCUL -2.46%53 3-Year Share Buyback Ratio is -40.90 as of Jun. 2026. GuruFocus rates OCUL with a GF Score™ of 53/100 and a GF Value™ of $4.53 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,188 Biotechnology companies, Ocular Therapeutix ranks worse than 80.13% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Ocular Therapeutix's current 3-Year Share Buyback Ratio was -40.90%.
The historical rank and industry rank for Ocular Therapeutix's 3-Year Share Buyback Ratio or its related term are showing as below:
OCUL'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -40.9 Med: -18.8 Max: -6.4
Current: -40.9
During the past 13 years, Ocular Therapeutix's highest 3-Year Share Buyback Ratio was -6.40%. The lowest was -40.90%. And the median was -18.80%.
OCUL's 3-Year Share Buyback Ratio is ranked worse than 80.13% of 1188
companies
in the Biotechnology industry
Industry Median: -11.85
vs OCUL: -40.90
Ocular Therapeutix (NAS:OCUL) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Ocular Therapeutix 3-Year Share Buyback Ratio Related Terms
OCUL vs HRMY, MLYS, BHVN: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Ocular Therapeutix's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's 3-Year Share Buyback Ratio falls into.
Ocular Therapeutix 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -40.90 mean?
Ocular Therapeutix (OCUL) has a 3-Year Share Buyback Ratio of -40.90 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Ocular Therapeutix and its competitors. According to the industry distribution chart, Ocular Therapeutix ranks #952 out of 1188 companies in the Biotechnology industry, placing it in the top 80.1%.
Is Ocular Therapeutix's 3-Year Share Buyback Ratio too high?
Ocular Therapeutix's current 3-Year Share Buyback Ratio is -40.90. Based on the distribution chart, Ocular Therapeutix ranks #952 out of 1188 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ocular Therapeutix has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's 3-Year Share Buyback Ratio compare to HRMY and MLYS?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #952 out of 1188 companies for 3-Year Share Buyback Ratio. This places Ocular Therapeutix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Ocular Therapeutix and its competitors. Ocular Therapeutix's current 3-Year Share Buyback Ratio is -40.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (OCUL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.53, compared to a current price of $11.11 — trading 145.3% above its estimated fair value. The current 3-Year Share Buyback Ratio is -40.90. Ocular Therapeutix's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Ocular Therapeutix (OCUL), the current 3-Year Share Buyback Ratio is -40.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (OCUL) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of $11.11 is trading 145.3% above its estimated GF Value™ of $4.53.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for OCUL:
3-Year Share Buyback Ratio: -40.90
GF Value™: $4.53 vs. price of $11.11 (145.3% above fair value)
No single metric tells the full story. See the OCUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
53GF Score
Get the complete analysis for OCUL
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUL has been successfully added to your 
